Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.58 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24360047 | 0.87 | NT5E (0.51) | NR4A2KDM4EALDH1A1HSD17B10NT5E | |
| SCHEMBL3344697 | 0.84 | NT5E (0.56) | NR4A2SOS2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3828474 | 0.81 | BACE1 (0.45) | NR4A2KDM4EALDH1A1HSD17B10NT5E | |
| SCHEMBL26390863 | 0.81 | KDM4E (0.45) | NR4A2KDM4EALDH1A1HSD17B10NT5E | |
| SCHEMBL3850835 | 0.81 | BACE1 (0.45) | NR4A2KDM4EALDH1A1HSD17B10NT5E | |
| SCHEMBL11837223 | 0.80 | NT5E (0.51) | NR4A2KDM4EALDH1A1HSD17B10NT5E | |
| SCHEMBL26406670 | 0.80 | ADRB2 (0.45) | NR4A2KDM4EALDH1A1NT5EACHE | |
| SCHEMBL11831900 | 0.80 | NT5E (0.44) | NR4A2SOS2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3345355 | 0.80 | NT5E (0.44) | NR4A2KDM4EALDH1A1HSD17B10NT5E | |
| SCHEMBL30106738 | 0.77 | NCF1 (0.55) | KDM4EALDH1A1HSD17B10NT5EACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567477-B1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| EP-2090566-A2 | Certain phenylacetic acids and derivatives | Novartis AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7202364-B2 | Certain phenylacetic acids and derivatives | NOVARTIS, AG (CH) | 2007-04-10 | — | — | US | disclosed |
| EP-1567477-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | Novartis AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | NOVARTIS AG (CH) | 2004-07-08 | — | — | US | disclosed |
| WO-2004048314-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | CYP2A6, HCAR2, CYP2B6 | NR4A2 795/4885SOS2 4388/4885KDM4E 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.